参考文献/References:
[1] Williams LK,Gruner CH,Rakowski H.The role of echocardiography in hypertrophic cardiomyopathy[J].Curr Cardiol Rep,2015,17(2):6.
[2] Elliott PM, Anastasakis A,Borger MA, et al.2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy[J].Kardiol Pol,2014,72(11):1054-1126.
[3] 熊峰,刘春霞,唐炯.肥厚型心肌病的诊断与治疗进展[J].心血管病学进展,2013,34(5):686-689.
[4] Kounas S,Demetrescu C,Pantazis AA,et al.The endocardial appearance is a poor discriminator of Anderson-Fabry disease from familial hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2008,51:2058-2061.
[5] Cavalcante JL,Barboza JS,Lever HM.Diversity of mitral valve abnormalities in obstructive hypertrophic cardiomyopathy[J].Prog Cardiovasc Dis,2012,54(6):517-522.
[6] Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy[J]. Lancet,2000,355(9197):58-60.
[7] Williams LK, Gruner CH, Rakowski H.The role of echocardiography in hypertrophic cardiomyopathy[J]. Curr Cardiol Rep,2015,17(2):6.
[8] Kitaoka H, Kubo T, Okawa M, et al. Utility of tissue Doppler imaging to predict exercise capacity in hypertrophic cardiomyopathy:comparison with B-type natriuretic peptide[J]. J Cardiol,2009,53(3):361-367.
[9] Ma G, Xu M, Gao W, et al. Left ventricular filling pressure assessed by exercise TDI was correlated with early HFNEF in patients with non-obstructive hypertrophic cardiomyopathy[J]. BMC Cardiovasc Disord,2014,14:194.
[10] Kitaoka H,Kubo T,Hayashi K, et al.Tissue Doppler imaging and prognosis in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy[J]. Eur Heart J Cardiovasc Imaging,2013,14(6):544-549.
[11] Teske AJ, de Boeck BW,Melraan PG, et al. Echocardiographic quantification of myocardial function using tissue deformation imaging,a guide to image acquisition and analysis using tissue Doppler and speckle tracking[J]. Cardiovasc Ultrasound,2007,5:27.
[12] Abozguia K, Nallur-Shivu G, Phan TT,et al. Left ventricular strain and untwist in hypertrophic cardiomyopathy:relation to exercise capacity[J].Am Heart J,2010,159(5):825-832.
[13] Garceau P,Carasso S,Woo A,et al. Evaluation of left ventricular relaxation and filling pressures in obstructive hypertrophic cardiomyopathy:comparison between invasive hemodynamics and two-dimensional speckle tracking[J]. Echocardiography,2012,29(8):934-942.
[14] Maron BJ, Maron MS. Hypertrophic cardiomyopathy[J]. Lancet,2013,381(9862):242-255.
[15] Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy[J]. Rev Esp Cardiol(Engl Ed),2014,67(1):58.
[16] Schaff HV, Dearani JA, Ommen SR, et al. Expanding the indications for septal myectomy in patients with hypertrophic cardiomyopathy:results of operation in patients with latent obstruction[J]. J Thorac Cardiovasc Surg,2012,143(2):303-309.
[17] Efthimiadis GK, Pitsis A, Pagourelias ED, et al. Surgical septal myectomy for hypertrophic cardiomyopathy in Greece:a single-center initial experience[J]. Hellenic J Cardiol,2014,55(2):132-138.
[18] Faber L, Ziemssen P, Seggewiss H. Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring[J]. J Am Soc Echocardiogr,2000,13:22-25.
[19] Nagueh SF.Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy[J]. J Am Coll Cardiol,1998,32:225-229.
[20] Faber L, Ziemssen P, Seggewiss H.Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring[J]. J Am Soc Echocardiogr,2000,13(12):1074-1079.
[21] Veselka J, Prochazkova S, Bolomova-Homolova I, et al.Effects of alcohol septal ablation for hypertrophic obstructive cardiomyopathy on Doppler Tei index: a midterm follow-up[J]. Echocardiography,2005,22(2):105-109.
[22] El-Jack SS, Nasif M, Blake JW, et al. Predictors of complete heart block after alcohol septal ablation for hypertrophic cardiomyopathy and the timing of pacemaker implantation[J].J Interv Cardiol,2007,20(1):73-76.
相似文献/References:
[1]王慧,饶莉.经导管主动脉瓣植入术的影像学研究进展[J].心血管病学进展,2015,(5):531.[doi:10.3969/j.issn.1004-3934.2015.05.002]
WANG Hui,RAO Li.Advances in Study of Imaging of Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2015,(4):531.[doi:10.3969/j.issn.1004-3934.2015.05.002]
[2]黄淮滨 刘甲兴.肥厚型心肌病治疗新靶点——钙脱敏治疗[J].心血管病学进展,2019,(7):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
HUANG HuaibinLIU Jiaxing.A Novel Target for Therapy in Hypertrophic Cardiomyopathy: Ca2+ desensitizer[J].Advances in Cardiovascular Diseases,2019,(4):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
[3]马秀英 贾锋鹏.肥厚型心肌病并发心房颤动的危险因素研究进展[J].心血管病学进展,2020,(12):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
MA XiuyingJIA Fengpeng.Update about the Risk Factors of Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(4):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
[4]邓清文,何森.肥厚型心肌病合并心房颤动的研究进展[J].心血管病学进展,2021,(4):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
DENG Qingwen,HE Sen.Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(4):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
[5]尚依一 刘罗 庞明杰 张艳.基因检测在肥厚型心肌病中的应用进展[J].心血管病学进展,2021,(6):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
SHANG Yiyi,LIU Luo,PANG Mingjie,et al.Gene Detection for Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(4):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
[6]王娟 杨艳敏.肥厚型心肌病发生缺血性卒中的危险因素和管理策略研究进展[J].心血管病学进展,2021,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
WANG Juan,YANG Yanmin.Risk Factors and Management Strategies of Ischemic Stroke in Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(4):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
[7]武志刚 孙佳莉 王巍.基于心脏磁共振成像的肥厚型心肌病患者早期峰值充盈率与舒张功能相关性的研究[J].心血管病学进展,2021,(7):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
WU Zhigang,SUN Jiali,WANG Wei.Correlation Between Early Peak Filling Rate and Diastolic Function in Patients with Hypertrophic Cardiomyopathy Based on Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2021,(4):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
[8]蓝庆肃 武锋超 马兰虎 韩冰 徐金 彭瑜 张钲.Mavacamten治疗肥厚型心肌病的研究进展[J].心血管病学进展,2021,(11):1028.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
LAN Qingsu,WU Fengchao,MA Lanhu,et al.Mavacamten in Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(4):1028.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
[9]李传伟,罗浩,曾春雨.肥厚型心肌病室间隔消减策略的研究进展[J].心血管病学进展,2022,(1):7.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.002]
LI Chuanwei,LUO Hao,ZENG Chunyu.Septal Reduction Therapy of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2022,(4):7.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.002]
[10]李珂 赵海娟 赵耀 黄松群 郭志福.肥厚型心肌病合并心房颤动的导管消融[J].心血管病学进展,2022,(5):399.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.004]
LI Ke,ZHAO Haijuan,ZHAO Yao,et al.Catheter Ablation of Hypertrophic Cardiomyopathy with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(4):399.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.004]